A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo In Patients With Overactive Bladder.

Trial Profile

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo In Patients With Overactive Bladder.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2014

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Feb 2014 Results from posthoc analysis of secondary endpoint (measures of nocturia) published in the Urology.
    • 03 Jul 2009 Tria locations added as reported by ClinicalTrials.gov.
    • 09 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top